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Abstract
Background: Adherence to recommendations and medication is deemed to be important for effectiveness of case
management interventions. Thus, reasons for non-adherence and effects on health-related quality of life (HRQoL)
should be fully understood. The objective of this research was to identify determinants of non-adherence to
medication and recommendations, and to test whether increased adherence improved HRQoL in patients after
myocardial infarction (MI) in a case management intervention.
Methods: Data were obtained from the intervention group of the KORINNA study, a randomized controlled trail of
a nurse-led case management intervention with targeted recommendations in the elderly after MI in Germany.
Reasons for non-adherence were described. Logistic mixed effects models and OLS (ordinary least squares) were
used to analyze the effect of recommendations on the probability of adherence and the association between
adherence and HRQoL.
Results: One hundred and twenty-seven patients with 965 contacts were included. Frequent reasons for non-adherence
to medication and recommendations were “forgotten” (22%; 11%), “reluctant” (18%; 18%), “side effects” (38%; 7%),
“the problem disappeared” (6%; 13%), and “barriers” (0%; 13%). The probability of adherence was lowest for disease
and self-management (38%) and highest for visits to the doctor (61%). Only if patients diverging from prescribed
medication because of side effects were also considered as adherent, 3-year medication adherence was associated
with a significant gain of 0.34 quality-adjusted life years (QALYs).
Conclusions: Most important determinants of non-adherence to medication were side effects, and to recommendations
reluctance. Recommended improvements in disease and self-management were least likely adhered. Medication
adherence was associated with HRQoL.
Trial registration: Current Controlled Trials ISRCTN02893746, retrospectively registered, date assigned 27/03/2009.
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Background
Coronary heart disease (CHD) is one of the leading
causes of mortality and its’ incidence is likely to increase
with increasing life expectancy [1]. It has been shown
that patients with CHD who have suffered a myocardial
infarction (MI) experienced significantly decreased
health-related quality of life (HRQoL) compared with
both, CHD patients without infarction and the general
population, as measured by generic instruments such as
EQ-5D-3 L and visual analog scale (VAS) [2, 3]. Despite
adherence is deemed to be a necessary condition for ef-
fective therapy, empirical evidence shows insufficient ob-
served and self-reported adherence to medication [4].
Besides adherence to medication, adherence to other
aspects of therapy, such as healthy lifestyle, disease man-
agement and reduced personal risk factors are also im-
portant for effective therapy [5]. However, in health care
provision, they have often been found to be poorly
addressed [6]. Improving adherence to medication and
healthy lifestyle is deemed to be important in heart dis-
eases, especially after MI, because continuous therapy
improves several clinical outcomes which are associated
with improved HRQoL [7]. The association of adherence
and HRQoL is less analyzed.
Case management programs are one approach to indi-
vidualized secondary prevention. These programs are de-
signed to improve adherence to medication and give
recommendations to encourage patients to make healthy
lifestyle choices, and optimal disease management [8]. It
was found in previous research, that despite better
knowledge, patients are often unable to implement healthy
lifestyles into their lives [9]. This problem was addressed
by randomized controlled trial (RCT) KORINNA, a
nurse-led case management which was designed to analyze
whether case management in elderly people with AMI can
postpone unplanned readmission or death [10]. Previous
evaluations showed that KORINNA can improve HRQoL
in the elderly after MI but did not improve unplanned
readmissions or death [11, 12]. It has not been extensively
analyzed which determinants of adherence exist in the
treatment group. There is some evidence about a positive
association between adherence to medication and clinical
outcomes in other settings [13–18]. But to the authors’
knowledge, there is little evidence about the impact of ad-
herence in case-management interventions, especially with
respect to nurses’ recommendations on HRQoL. There-
fore, we analyzed this question in detail.
To improve adherence, its’ determinants need to be
understood. There are some theoretical frameworks which
suggest that the patient’s belief about the therapy’s effect-
iveness and costs have an impact on adherence [19]. Em-
pirically, associations between patients’ characteristics and
adherence were also studied. However, studies about pa-
tient reported reasons for non-adherence in heart diseases
are rare [20, 21]. A recent study also calls for further re-
search on patient-specific drivers for adherence to medica-
tion in post-MI patients [22]. This issue will also be
assessed in this paper.
Increasing knowledge about non-adherence, its deter-
minants, and effects on patient-relevant outcomes could
help to address underlying problems, and to improve the
effectiveness of case management interventions. There-
fore, the first objective of this study was to identify de-
terminants of non-adherence to both medication and
recommendations in a case management intervention.
The second objective was to verify whether adherence
was associated with improved HRQoL.
Methods
The data were obtained from the intervention group of
the KORINNA RCT, which evaluated the effectiveness
and cost-effectiveness of a case management interven-
tion by trained nurses in elderly patients with an acute
myocardial infarction.
The KORINNA trial
The study design, intervention and results of the
KORINNA trial are described elsewhere [10, 11, 23–25].
In short, 340 patients were recruited between September
2008 and May 2010. Recruited patients were 65+ years,
and hospitalized as a result of MI at the Central Hospital
of Augsburg, Germany. Enrollment and randomization
took place between September 2008 and May 2010. Pa-
tients who lived in a nursing home or planned to move
there, patients with severe comorbidities and a life ex-
pectancy of less than 1 year, or patients who were unable
to communicate adequately in German were excluded.
Retrospectively, 11 patients were excluded because they
died or withdrew consent before hospital discharge. The
trial was approved by the Ethics Committee of the
Bavarian Chamber of Physicians (ISRCTN02893746).
The case-management
The intervention was characterized by structured inter-
views carried out as home visits or telephone calls for
up to 3 years after discharge from hospital. According to
the specific needs, resources, and problems of each pa-
tient, nurses gave recommendations concerning healthy
lifestyle and disease management. In the first year, an
intervention contact was arranged at least every
3 months, and every 6 months in the second and third
years. Adherence to recommendations and medication
was evaluated only in the intervention group at each
contact. Patients who did not adhere to medication or
recommendation were asked for their reasons which were
categorized. Further information with respect to categor-
ies, including examples are given in Additional file 1:
Appendix A.
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Utilized sample for adherence evaluation
Because adherence could be only assessed in patients of
the intervention group with at least two contacts with a
nurse, other patients were excluded. Complementary
and alternative therapies, and therapies or recommenda-
tions that could not be applied for objective reasons,
such as readmission to hospital, were excluded. In the
second analyses of the association of adherence and
HRQoL only patients enrolled until the end of the trail
or until death were included.
Operationalization of medication and recommendation
adherence
Included recommendations given by the study nurse
concerned healthy lifestyle and were categorized by pre-
defined classes and revised ex post. The urgency of rec-
ommendations with respect to the patient’s situation was
judged by the nurse as “high”, “medium”, or “low”. Fur-
ther information with respect to categories, including
examples are given in Additional file 1: Appendix A.
Adherence to a single recommendation was defined as
fully executing the advice. If a patient did not adhere to
at least one highly urgent or two medium urgent
recommendations of a contact, s/he was considered
non-adherent at that contact until the next contact.
Non-adherence to a medication application was defined
if a patient had paused or discontinued therapy or chan-
ged the dose. Patients who had not taken one or more
medication as prescribed were considered non-adherent
at that contact. Otherwise, if non-adherence to medica-
tion was not identified, adherence was assumed.
If a patient was adherent for 80% of participation time,
s/he was defined as 3-year adherent. This threshold is
used to allow for some non-adherence which can be
considered to be not problematic with respect to effi-
cient therapy [26]. The 80% threshold is commonly used
but somewhat arbitrary. Therefore, sensitivity analyses
with 60 and 90% thresholds to adherence were done.
Non-adherence because of side effects in case of medica-
tion could be desirable, as they could be a sign of inappro-
priate therapy, or not desirable because there may be no
better alternative. Because of this uncertainty, a second def-
inition of medication adherence was used to analyze the as-
sociation of adherence and HRQoL, where non-adherence
to medication because of side effects was allowed.
Potential determinants of non-adherence
Patient-reported reasons for non-adherence can be con-
sidered as causal drivers of adherence, if one assumes
that patients answered honestly. Some recommendations
might have been harder to adhere to than others.
Changing nutrition for example might be more difficult
than to make an appointment with the doctor.
Therefore, besides patient-reported reasons, the type of
recommendation was considered to be a potential driver
of adherence.
Operationalization of HRQoL
HRQoL was operationalized by VAS, where 100 represents
perfect health and zero worst health possible [11]. It was
assessed at each intervention contact. A case management
intervention is a complex intervention which addresses
multiple aspects in patients’ lives. Therefore, complex in-
terventions require multi-dimensional outcome measure-
ment like quality of life. In contrast to cardiovascular
clinical outcomes like cardiovascular events, VAS-points
reflect all patient relevant health problems including co-
morbidities. It is a measure of patient-reported health and
is therefore considered to describe subjective health more
appropriately than population-based valuation methods
[27, 28]. A linear relationship was assumed between two
VAS observations. QALYs were calculated as VAS-adjusted
life years (VAS-ALs), as done in previous research [25]. In
the event of death, a linear decline from the last observa-
tion to zero at the date of death was assumed. In a sensitiv-
ity analysis, we assumed the last observed VAS value to be
constant until the event of death, because otherwise the
timing of the last meeting could bias overall VAS-AL.
Statistical methods
Simple descriptive statistics were used to present reasons
for non-adherence, patients’ baseline characteristics and
3-year outcomes. Baseline values correspond to the first
observation of a given variable. There were no missing
values in baseline variables.
To analyze the impact of recommendation type on the
probability of adherence, a generalized logistic mixed ef-
fects model with individual random intercept was used.
In this type of model, the intercept is allowed to vary by
individual. Patient specific intercepts are efficient to con-
trol for time-invariant heterogeneity within individuals
in panel data, and therefore reduce the omitted variable
bias [29]. The effect was controlled by recommendations’
urgency. Urgency is considered to be a potential con-
founder since it might be associated with both, the type of
recommendation and the probability of adherence.
To follow the second objective, two models were used
which were controlled by baseline-variables body mass
index (BMI), New York Heart Association (NYHA)
functional classification, age, gender, number of comor-
bidities and stressful events in follow-up.
First, a linear mixed effects model with random inter-
cept, a variance component (VC) covariance structure
and restricted maximum likelihood (REML) estimation
was used. The VC covariance structure model allows
each random effect to have a different variance. In con-
trast to maximum likelihood estimation the REML
estimation is most appropriate for small sample sizes
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[30]. With this model the hypothesis that changing to
adherence changes VAS was tested. Because of the risk
of reversed causality, a lagged variable design was used
which is appropriate to reduce that problem [31]. Ac-
cordingly, we estimated the effect of getting adherent to
medication or a recommendation of a former contact on
VAS at the next contact. Measures of adherence were
operationalized as both, a fixed and a random effect.
The fixed effects component is the variable of interest. It
represents the effect of getting adherent. A random ef-
fect controls for the individual variance of this effect. Be-
cause of the random intercept, this model also controls
for patient-specific, time-invariant heterogeneity. Add-
itionally, the effect was controlled for days expired since
randomization, as VAS and adherence were assumed to
be affected by the passage of time.
Second, ordinary least squares (OLS) were used to test
whether 3-year adherence was associated with overall
VAS-AL gained. Because OLS is sensitive to outliers, a
sensitivity analysis with least trimmed squares was used
to perform an outlier robust estimation [32].
Although the problem of reversed causality was con-
trolled by the lagged variable design, it could not be cut
out completely. Therefore, the reversed relationship of
adherence and VAS was analyzed in a sensitivity ana-
lysis, where the effect of VAS at one intervention contact
on adherence until the next contact was also estimated.
This analysis is presented in Additional file 1: Appendix
B. Because the results were not significant, risk of re-
versed causality was assumed to be small.
All statistical analyses were conducted in SAS 9.3.
Results
Of 161 patients from the KORINNA intervention group
127 patients were included. Thirty-four patients were ex-
cluded because they never had an intervention contact.
From the analyses of 3-year adherence, 11 patients were
excluded because they left the trial before the end for
reasons other than death. Baseline characteristics and
3-year outcomes are presented in Table 1.
Patients were mostly male and between 65 and 91 years
old. About 43% suffered from comorbidities, diabetes,
congestive heart failure, or both. Three-year adherence
to medication was higher than to recommendations
(87% vs. 68%). Within 3 years, patients achieved 1.82
VAS-ALs (min. 0.07, max. 2.81). The sensitivity analysis
with fixed VAS until death affected three patients and
did not change overall results (results are not reported).
Determinants of medication adherence
Within 3 years, 127 included patients received 965 inter-
vention contacts. Non-adherence to prescribed medica-
tion was observed in 72 contacts. Of those, a changed
dose (33%) or paused medication (32%) was observed
most frequently. Side effects, the most important reason
for non-adherence to medication, mostly led to discontin-
uations (44%) or changed doses (37%). Forgetfulness, the
second most frequently reported reason, was mostly asso-
ciated with paused therapies (94%). Reluctant patients
changed their dose in 54% of cases (Additional file 1:
Appendix Table D1, C1).
Determinants of recommendation adherence
For 771 of 889 recommendations adherence was
assessed. Eighty recommendations concerned natural
therapies and were excluded. Finally 691 were included
in the analysis. Thereof, 314 were not fully adhered to
(Additional file 1: Appendix Table C2).
Mostly patients did not report a clear reason for
non-adherence (21%). Of evaluable reasons, reluctance
was the most frequent, followed by disappearance of the
underlying problem and barriers. In case of recom-
mended doctor visits disappearance of the underlying
problem (21%), forgetfulness (15%), and postponed visits
(14%) were most frequently reported. In case of recom-
mended improvements in control of vital signs and
blood glucose, reluctance (39%) and forgetfulness (17%)
were the major reasons (details in Additional file 1:
Appendix Table C2). Adjusted results from logistic
estimations showed that the probability of adherence
Table 1 Patient baseline characteristics and 3-year outcomes
N = 127 N/mean %/SD
Baseline characteristics
Male (n, %) 81 63.8
Diabetes (n, %) 34 26.8
CHF (n, %) 34 26.8
Neither diabetes nor CHF (n, %) 72 56.7
Diabetes or CHF (n, %) 42 33.1
Diabetes and CHF (n, %) 13 10.2
Age (mean, SD) 74.7 5.7
VAS (mean, SD) 63.3 17.9
BMI (mean, SD) 27.0 4.0
3-year outcomes (N = 116)
VAS-AL (mean/SD) 1.82 0.62
Adherent to medications (n, %)a 101 87.1
Adherent to recommendations (n, %)a 79 68.1
Adherent to medications and
recommendations (n, %)a
72 62.1
Non-adherent to medications and
recommendations (n, %)a
8 6.9
Non-adherent to either medications
or recommendations (n, %)a
36 31.0
aAdherence refers to 3-year adherence
BMI body mass index, CHF chronic heart failure, N number of patients,
SD standard deviation; VAS visual analog scale, VAS-AL VAS-adjusted life years
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was highest if visits to the doctor were recommended
(61%), and lowest in case of disease and self-management
(38%), nutrition (40%), and control of vital signs and blood
glucose (43%) (Table 2).
Adherence and HRQoL
Three-year adherence to recommendations or medication
was not significantly associated with VAS-AL (− 0.06,
p = 0.52; 0.21, p = 0.13). Becoming adherent to recom-
mendations or medication did not cause significant
changes in VAS points (− 2.04, p = 0.11; − 1.47, p = 0.4)
(Additional file 1: Appendix Table D1). Significant effects
were only found if adherent patients included patients
who diverged from prescribed therapy because of side ef-
fects. In this case, in 3-year medication adherent patients
HRQoL increased by 0.40 VAS-AL (Table 3, details in
Additional file 1: Appendix Table D1).
Sensitivity analyses with 60 and 90% thresholds to ad-
herence did not show significant results (Additional file 1:
Appendix Table D2). Outlier robust estimations barely
changed estimates. The significant association of medica-
tion adherence and VAS-AL remained but decreased to
0.32 VAS-AL (Additional file 1: Appendix Table D3).
Discussion
To increase the effectiveness of case management inter-
ventions, adherence to case manager’s recommendations
and to prescribed medication is deemed to be important.
To the authors’ knowledge, the role of adherence in case
management interventions with respect to HRQoL and
reasons for non-adherence are not fully understood and
rarely studied. Based on the intervention group in the
KORINNA trial, determinants of non-adherence to
medication and recommendations in patients after MI
were identified first. Second, it was verified whether
increased adherence was associated with improved
HRQoL in those patients.
Determinants of adherence
It was found that side effects, forgetfulness, and being
reluctant were the most important reasons for non-
adherence to medication. Patients with side effects mostly
discontinued therapy or changed the dose. On the one
hand, this could have been the right decision and in con-
cordance with the prescribing physician. On the other
hand, it could be hazardous. Based on the available data,
this could not be evaluated. Forgetfulness was more often
associated with paused applications than with discontinu-
ation, and never with a change in dose. Therefore, patients
sometimes forgot the application rather than the correct
dosage. Reluctance was more often associated with chan-
ged doses than with discontinuation or other kinds of
non-adherence. This implies that patients were usually
convinced about the medication’s necessity, but did not
believe in the necessity of prescribed dosing.
Reasons for non-adherence to recommendations dif-
fered between the different types of recommendations.
Mostly, visits to the doctor, improvements in nutrition,
and improved control of vital signs and blood glucose
were recommended. In case of non-adherence to doc-
tor’s appointments, the most frequent reason was the
disappearance of the underlying problem. This might be
problematic if abating symptoms, such as high blood
glucose levels or angina pectoris, should still be treated
[7]. The most important reason for non-adherence to
improvements in control of vital signs and blood glucose
was being reluctant, which can be problematic especially
in post-MI patients [7]. Adherence to improvements in
nutrition is usually considered to be important. For ex-
ample achieving body fat goals is recommended in MI
patients [7]. The finding that non-adherence to nutrition
Table 2 Generalized logistic mixed effects model – the effect of recommendation types and urgency on adherence
N = 686 (110 patients) Adherence to recommendations
Variable OR 95% CI limits Probability of adherence in % 95% CI limits
Type of recommendation (ref = visit to the doctor)
Others 0.55 0.25 1.21 46.25 27.82 65.77
Disease and self-management 0.39 0.17 0.88 37.69 21.48 57.21
Mobility and fall prevention 0.53 0.25 1.11 45.22 27.91 63.77
Control of vital signs and blood glucose 0.49 0.31 0.77 43.42 31.56 56.08
Nutrition 0.42 0.24 0.72 39.66 28.25 52.33
Visit to the doctor 61.06 51.41 69.92
Urgency (ref = low)
High 1.87 0.80 4.36 50.59 42.67 58.47
Medium 1.90 0.78 4.58 50.95 40.97 60.86
Low 35.41 19.54 55.30
CI confidence interval, OR odds ratio, ref reference
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was mostly due to barriers is in line with previous re-
search which found that patients find it hard to adhere
to diet restrictions [33].
It was found that patients were more likely to visit a
doctor than to improve self- and disease management,
nutrition, or control of vital signs and blood glucose. It
was also found that 3-year adherence to medication was
more frequent than to recommendations. Furthermore,
non-adherence and reluctance were bigger problems in
recommendations than in medications. Therefore, the
findings of this research support existing evidence that
patients have greater belief in medical therapy than in
healthy lifestyle and disease management-related recom-
mendations [33]. They also suggest that patients have
more problems in explaining their reasons for non-
adherence to recommendations than to medication,
because patients did not report specific reasons for
non-adherence to recommendations more frequently
than to medication.
The association of adherence and HRQoL
Results about the effect of adherence on HRQoL were
sensitive to the definition of adherence. With the first
definition, significant effects of adherence on HRQoL
could not be identified. With the second definition of
medication adherence (side effects were allowed) a sig-
nificant increase of 0.34 VAS-AL was found in patients
who were 80% of 3-year follow up adherent to medica-
tion. The result has shown to be robust to outliers. This
is some evidence for the conclusion that non-adherence
because of side effects was desirable in the KORINNA
trail. However, this finding is of limited generalizability
because the study population was educated by the
study-nurses and can therefore be assumed to be more
qualified for autonomous therapy decisions than the
general population [10]. An explanation for the positive
effect of medication adherence, as defined in the second
definition, on VAS-AL but not on VAS is the consider-
ation of long-term effects and length of periods in differ-
ent health states. We could not find significant effects of
adherence to recommendations on VAS or VAS-AL.
There are several explanations possible. First, the recom-
mendations’ quality was inadequate to improve health.
However, nurses had a special evidence-based training
for post-MI care, which should have insured high
quality. It was found that adherence to medication but
not to recommendations showed significant effects. This
might indicate that in contrast to recommendations,
medication was more effective with respect to VAS-AL.
Second, there might have been ceiling effects in recom-
mendation and medication adherence, as the study
population comprised only the intervention group and
the intervention was designed to guarantee high adher-
ence. Third, the power in the intervention group might
not have been big enough to identify significant effects.
Fourth, the threshold of 80% might not comply with the
true critical level of non-adherence. Critical levels of ad-
herence are rarely studied [34]. Significant estimates
were only found in the primary analysis but not in sensi-
tivity analyses with 60 and 90% thresholds to adherence.
Therefore, the 80% threshold seems to be valid to iden-
tify significant effects in the KORINNA’s intervention
group. Besides, the utilized definition of medication
adherence is similar to existing research. Furthermore,
recommendations were only necessary if there was some
kind of non-optimal behavior. Therefore, recommenda-
tions are to some degree already an indicator of
non-adherence. Lastly, even though additional analyses
about the effect of VAS on adherence did not show sig-
nificant results, reversed causality cannot be ruled out.
Because of the single-center design of the KORINNA
trial, the findings are of limited generalizability. Because
a very specific intervention was analyzed, the results
might only apply to patients after MI in similar interven-
tions. An advantage of this study is the panel data, which
allowed controlling for unobserved, time-invariant het-
erogeneity in the mixed effects models. Panel data con-
sidered to be more valid to identify causal associations
than cross-sectional data, as often utilized in surveys
concerning the analysis of adherence [35]. Another ad-
vantage is the huge number of interviews and the pro-
spective study design. Despite the problems discussed,
this study contributes to the limited existing evidence
about determinants of non-adherence and effects of ad-
herence, especially to recommendations.
Conclusions
Patient-reported reasons for non-adherence and recom-
mendation types were considered to be determinants of
adherence. It was found that reasons for non-adherence
Table 3 Results of OLS estimation: Association of adherence and VAS-AL
N = 116 patients VAS-AL VAS-AL (adherent in presence of side effects)
3-year adherence Estimate SE Pr > |t| Estimate SE Pr > |t|
Adherence to medication 0.21 0.14 0.1263 0.40 0.18 0.0270
Adherence to recommendations −0.06 0.10 0.5159 −0.08 0.10 0.4033
All results are controlled for baseline variables (BMI, NYHA, Age, gender, number of comorbidities) and stressful event in follow-up
BMI body mass index, NYHA classification of heart failure of the New York Heart Association, SE standard error, VAS visual analog scale, VAS-AL VAS-adjusted life
years, LME linear mixed effects
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differed with type of therapy (healthy lifestyle vs. medi-
cation) and type of recommendations with respect to
healthy lifestyle. We found different reasons for
non-adherence. For example reluctance (side effects)
was the most important for non-adherence recommen-
dations (medication). We also found that different rec-
ommendations were associated with different risks of
non-adherence. The greatest risk of non-adherence to
recommendations was associated with disease and
self-management, visits no the doctor was significantly
more likely to be adhered. Knowing about these deter-
minants of non-adherence will help case-managers to
take appropriate and stratified precautions to prevent
non-adherence in dependence of the type of therapy.
The effect of adherence on HRQoL was sensitive to the
definition of adherence. Patients who were adherent to
medication within 3 years only gained 0.34 VAS-AL if
non-adherence because of side effects was allowed. There-
fore, it can be concluded that non-adherence to medication
because of side effects was beneficial in the analyzed study
population. However, the intervention group was schooled
and can therefore be considered to be more qualified for
therapy decisions than the general population.
Additional file
Additional file 1: Appendix A. Categories of recommendations and
reasons for non-adherence. This file describes the definition of categories
of recommendations (Table A1) and of the categories of reasons for
non-adherence (Table A2). Appendix B. Impact of VAS on adherence.
This file motivates and describes methods used for the analysis of
reversed causality between adherence and VAS. Table B1 presents
results from the logistic mixed effects model. Appendix C. Reasons for
non-adherence. This file presents descriptive statistics about the reasons
for non-adherence. Table C1 relates reasons for non-adherence to types
of non-adherence. Table C2 relates reasons for non-adherence to
recommendation types. Appendix D. The association of adherence and
HRQoL. This file presents detailed results of the primary analyses of the
association of adherence and VAS and VAS-AL (Table D1). Table D2
summarizes sensitivity analyses with varying thresholds to adherence.
Table D3 summarizes sensitivity analyses with outlier robust least
trimmed squares estimations. (DOCX 48 kb)
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